Your browser doesn't support javascript.
loading
A Comprehensive Retrospective Analysis of EVO/EVO+ Implantable Collamer Lens: Evaluating Refractive Outcomes in the Largest Single Center Study of ICL Patients in the United States.
Albo, Camila; Nasser, Taj; Szynkarski, David Thomas; Nguyen, Ngoc; Mueller, Brett; Libfraind, Lauren; Parkhurst, Gregory.
Afiliación
  • Albo C; Department of Ophthalmology, University of Texas Health San Antonio, San Antonio, TX, USA.
  • Nasser T; Department of Ophthalmology, Parkhurst NuVision, San Antonio, TX, USA.
  • Szynkarski DT; Department of Ophthalmology, Parkhurst NuVision, San Antonio, TX, USA.
  • Nguyen N; Department of Ophthalmology, Medical City Plano, Plano, TX, USA.
  • Mueller B; Department of Ophthalmology, Parkhurst NuVision, San Antonio, TX, USA.
  • Libfraind L; Department of Ophthalmology, Mueller Vision, Fort Worth, TX, USA.
  • Parkhurst G; Department of Ophthalmology, Parkhurst NuVision, San Antonio, TX, USA.
Clin Ophthalmol ; 18: 69-78, 2024.
Article en En | MEDLINE | ID: mdl-38223817
ABSTRACT

Purpose:

We evaluate visual outcomes in patients with EVO/EVO+™ (posterior chamber phakic intraocular lens with a central port) within approved United States (US) age and refractive range indications. Patients and

Methods:

This single-center retrospective study evaluated one-month, single-center postoperative data for 225 eyes meeting inclusion criteria and undergoing EVO/EVO+ implantation from April to October 2022. Data included lens size (mm), lens power (diopters of spherical and cylindrical power), preoperative best corrected visual acuity, preoperative spherical equivalent from manifest refraction, achieved postoperative uncorrected visual acuity, postoperative refraction, intraocular pressure (mmHg), and adverse events.

Results:

A total of 225 eyes underwent EVO/EVO+ Implantable Collamer Lens (ICL) implantation from April to October 2022, with 51.5% receiving toric lenses. The most common ICL size was 12.6mm (56.4%), followed by 13.2mm (27.5%), 12.1mm (15.1%), and 13.7mm (0.9%). Among patients with preoperative BCVA of 20/20 or better (149 eyes), 95.2% achieved postoperative UCVA of 20/20 or better, and 99.3% achieved UCVA of 20/25 or better at postoperative month one. About 75% of eyes were within a spherical equivalent target of ±0.50 D and 94% within ±1.00 D. Toric ICLs were implanted in 116 eyes (51.8%). Of these, anticipated residual cylinder >1 diopter was seen in 21 eyes (18.1%) resulting in three rotations, three explants, and three laser vision correction (LVC) enhancements. The postoperative adjustment rate (including rotations, exchanges, and LVC enhancement) was minimal (4.8%). Incidence of major adverse events was 0%.

Conclusion:

Our study, the largest US single-center analysis of EVO/EVO+ ICL implantation, demonstrates strong early results and infrequent adverse events, supporting ICL safety and effectiveness. High predictability and favorable visual outcomes, including 20/20 or better, highlight the reliability of this technology. Despite study limitations, our findings underscore this technology's effectiveness. Future research should refine patient criteria and assess long-term outcomes in this evolving landscape.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Clin Ophthalmol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Nueva Zelanda
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Clin Ophthalmol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Nueva Zelanda